Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review-Reference-Cited by-同舟云学术

Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review

Published:2019-01-31 Issue:7 Volume:60 Page:1610-1625
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Salles Gilles A.¹,Pettengell Ruth²,Cordoba Raul³,Długosz-Danecka Monika⁴^ORCID,Jurczak Wojciech⁴,Tilly Hervé⁵

Affiliation:

1. Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d‘Hématologie, Université Lyon-1, Lyon, France;

2. St George’s University of London, London, UK;

3. Lymphoma Unit, Fundación Jiménez Díaz University Hospital, Madrid, Spain;

4. Department of Hematology, Jagiellonian University, Kraków, Poland;

5. Department of Haematology, Université de Rouen, Rouen, France

Funder

Servier

AbbVie

Amgen

BMS

Celgene

Gilead

Janssen

Novartis

Pfizer

Roche

Takeda

Karyopharm

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1564828

Reference47 articles.

1. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project

3. Relapsed/Refractory Diffuse Large B-Cell Lymphoma

4. Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Patterns and Costs Among US Patients With Diffuse Large B-Cell Lymphoma not Treated With 2L Stem Cell Transplantation;Future Oncology;2024-03

2. Glofitamab as a salvage treatment for B‐cell lymphomas in the real world: A multicenter study in Taiwan;Cancer;2024-02-02

3. T-Cell Engaging Antibodies in Diffuse Large B Cell Lymphoma—An Update;Journal of Clinical Medicine;2023-10-25

4. Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial;Nature Medicine;2023-09-14

5. CAR T in patients with large B‐cell lymphoma not fit for autologous transplant;British Journal of Haematology;2023-04-20